## Sesamol inhibits atherogenic LDL-induced endothelial cell senescence in vivo and in vitro

Hong-Kai Huang <sup>1,\*</sup>, Fang-Yu Chen <sup>2,\*</sup>, Kuan-Hsiang Ting <sup>3,\*</sup>, Chih-Chung Feng <sup>2</sup>, Chia-Ming Chang <sup>2</sup>, Chu-Huang Chen <sup>4,5</sup>, Ming-Yi Shen <sup>2</sup>

**OBJECTIVE** Highly electronegative L5 low-density lipoprotein (LDL), an atherogenic LDL, induces endothelial cell (EC) senescence and has been implicated in the progression of atherosclerosis. We examine whether sesamol, a natural organic compound and component of sesame oil, prevents EC senescence induced by electronegative LDL (L5) and to investigate the underlying mechanisms. METHODS Syrian hamsters, which have a LDL profile similar to that of humans, were fed a normal chow diet (control), a high-fat diet (HFD), or a HFD supplemented with the administration of 50 or 100 mg/kg sesamol via oral gavage (HFD+sesamol) for 16 weeks (n=10 per group). Among these groups, we compared plasma L5 levels and aortic endothelial senescence in the aortic arch. In vitro, we examined the effects of sesamol on human aortic endothelial cell (HAEC) senescence and signaling pathways induced by L5. RESULTS Hamsters in the HFD group had higher plasma L5 levels than did the HFD+sesamol groups or control group. Beta-galactosidase (gal) staining showed that aortic endothelial senescence was markedly increased in the aortic arch of the HFD group but not in that of the HFD+sesamol groups when compared with the control In vitro, treatment of HAECs with sesamol (1-3 µM) blocked L5-induced EC senescence in a dose-dependent manner. Sesamol also markedly inhibited the L5-induced phosphorylation of p38 MAPK and p53 activation and increased Mdm2 and phosphorylation of Akt. CONCLUSION The critical findings of this study suggest that sesamol may provide protection against atherosclerosis and the development of cardiovascular disease in humans.

Key words: sesamol; atherogenic LDL; endothelial cell senescence; Syrian hamsters; p53

**Foundation item:** The project supported by the National Science Council of Taiwan (NSC102-2320-B-039-058) and China Medical University, Taiwan (CMU102-N-02 and CMU103-N-08)

**Corresponding author:** Ming-Yi Shen, E-mail: shenmy1124@gmail.com, Tel: +886-4-22052121 ext. 7502

<sup>&</sup>lt;sup>1</sup>Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan

<sup>&</sup>lt;sup>2</sup>Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

<sup>&</sup>lt;sup>3</sup>Department of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung, Taiwan;

<sup>&</sup>lt;sup>4</sup>Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, United States

<sup>&</sup>lt;sup>5</sup>Vascular and Medicinal Research, Texas Heart Institute, Houston, Texas, United States

<sup>\*:</sup> These authors contributed equally to this work.